The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the
past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the
United States. Current targeted strategies offer limited clinical benefits and the overall survival rate
for CRC remains low. Improved understanding of the molecular changes associated with CRC that
control growth factor signaling and evasion of cell death allow for the development of improved
targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
Keywords: Clinical, colorectal cancer, DPYD, RAS, targeted therapy, TRAIL.
Rights & PermissionsPrintExport